Heerlen, NL, 05 Nov 2013 07:15 CET
Royal DSM, the Life Sciences and Materials Sciences company, today reported a third quarter EBITDA of €342 million compared to €270 million in Q3 2012. This improvement of 27% was realized despite an ongoing challenging macro-economic environment.
Commenting on the results, Feike Sijbesma, CEO/Chairman of the DSM Managing Board, said: “I am pleased to report increased profitability in all our business clusters despite the initial impact from adverse currency movements and a continued challenging macro-economic environment. Nutrition continued its good performance notwithstanding some headwinds that emerged towards the end of Q3. Materials Sciences also delivered solid performance with higher profits.
Our focus remains on the full integration of acquisitions and delivery of synergies, which together with continued success in our wide-ranging Profit Improvement Program will help improve DSM’s returns. Current trading conditions are similar to those experienced at the end of Q3, while foreign exchange rates deteriorated. Nevertheless, we are firmly on track to deliver a significant increase in EBITDA for the full year. The 2013 outlook given at our Capital Markets Day remains unchanged.”
|Q3 2013||Q3 2012||+/-||in € million||volume||price/mix||exch. rates||other|
|Q3 2013||Q3 2012||+/-||in € million||Jan - Sep 2013||Jan - Sep 2012||+/-|
|148||111||33%||Core net profit||433||378||15%|
|136||103||32%||Net profit, before exceptional items||398||362||10%|
|117||81||44%||Net profit, after exceptional items||348||267||30%|
|0.86||0.67||28%||Core EPS (€/share)||2.53||2.29||10%|
|0.76||0.61||25%||Net EPS before exceptional items, (€/share)||2.27||2.15||6%|
|0.65||0.47||38%||Net EPS after exceptional items, (€/share)||1.98||1.57||26%|
|310||253||Cash flow from operations||463||547|
|175||186||Capital expenditures (cash)||507||474|
|Net debt||2,043||1,668 *|
* year-end 2013
You can find the press release in full, including financial statements, below.